| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |
oxcarbazepine did not meet the criteria of being an inhibitor or inducer of CYP3A. oxcarbazepine has not been evaluated in the literature showing its role of altering the activities of CYP2C19.
- Criteria not met: drugs evaluated in clinical PK interactions studies that do not meet the inclusion criteria (see Methods).
- Not evaluated in the literature: drugs implicated as inhibitors and inducers of CYP enzymes without reported clinical PK interaction studies.
Footnotes and References
|a.||clinical PK interaction studies referred to in product information.|
|b.||likely to be a major inhibitor based on subjective evaluation (≥ 2-fold AUC increase or ≥ 50% decrease in clearance of in vivo CYP probe).|
|c.||likely to be a major inducer based on subjective evaluation (≥ 2-fold decrease in AUC or ≥ 50% increase in clearance of in vivo CYP probe).|
|d.||poster found at http://www.klinikum.uni-heidelberg.de/fileadmin/medizinische_klinik/Abteilung_6/pdf/Posterpreis_VKliPha2008_Bayer.pdf|
|1.||Bertilsson L, Tybring G, Widen J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. British Journal of Clinical Pharmacology 1997; 44: 186-89.[PubMed]|
|2.||Gough PA, Curry SH, Araujo OE, Robinson JD, Dallman JJ. Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. British Journal of Clinical Pharmacology 1982; 14: 739-42.[PubMed]|
|3.||Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ. Diazepam interaction with antituberculosis drugs. Clinical Pharmacology & Therapeutics 1981; 29: 671-78.[PubMed]|
|4.||Lefebvre RA, Flouvat B, Karolactamisier S, Moerman E, Vanganse E. Influence of lansoprazole treatment on diazepam plasma concentrations. Clinical Pharmacology & Therapeutics 1992; 52: 458-63.[PubMed]|
|5.||Gugler R, Hartmann M, Rudi J, Brod I, Huber R, Steinijans VW, Bliesath H, Wurst W, Klotz U. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. British Journal of Clinical Pharmacology 1996; 42: 249-52.[PubMed]|
|6.||Sanz EJ, Bertilsson L. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo. Therapeutic Drug Monitoring 1990; 12: 297-99.[PubMed]|
|7.||Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, Toyoki T. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clinical Pharmacology & Therapeutics 1995; 58: 155-64.[PubMed]|
|8.||Hedaya MA, El-Afify DR, El-Maghraby GM. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharmaceutics & Drug Disposition 2006; 27: 103-10.[PubMed]|
|9.||Wire MB, Shelton MJ, Studenberg S. Fosamprenavir - Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clinical Pharmacokinetics 2006; 45: 137-68.[PubMed]|
|10.||Schellens JHM, Vanderwart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. Journal of Pharmacology and Experimental Therapeutics 1989; 249: 638-45.[PubMed]|
|11.||Abernethy DR, Greenblatt DJ, Morse DS, Shader RI. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. British Journal of Clinical Pharmacology 1985; 19: 51-54.[PubMed]|
DisclaimerWARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.